Serum Proteins Linked to IL28B Genotype in Chronic Hepatitis C Patients
Author Information
Author(s): Cyr Derek D., Lucas Joseph E., Thompson J. Will, Patel Keyur, Clark Paul J., Thompson Alexander, Tillmann Hans L., McHutchison John G., Moseley M. Arthur, McCarthy Jeanette J.
Primary Institution: Duke University Medical Center
Hypothesis
How does the IL28B genotype affect serum protein levels in chronic hepatitis C patients?
Conclusion
The IL28B polymorphism is associated with lower serum levels of corticosteroid binding globulin, but does not mediate treatment response.
Supporting Evidence
- The IL28B treatment response genotype was significantly associated with lower serum levels of corticosteroid binding globulin.
- CBG metaprotein was associated with treatment response, but this association was attenuated when both IL28B genotype and CBG were included in the model.
- 41 patients with chronic hepatitis C were analyzed for the study.
Takeaway
This study looked at how a specific gene affects proteins in the blood of people with hepatitis C, finding that one protein is linked to a gene that helps predict treatment success.
Methodology
Patients were genotyped for IL28B and proteomic profiles were generated using LC-MS/MS analysis.
Potential Biases
Potential biases may arise from the small sample size and the specific population studied.
Limitations
The study was based on a relatively small number of patients, which may limit the generalizability of the findings.
Participant Demographics
The cohort included 41 patients, predominantly Caucasian (78%), male (61%), with a mean age of 47.4 years.
Statistical Information
P-Value
9.2×10−6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website